Eurosurv. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−J

[tetano]

• Annabel A Powell[SUP]1[/SUP] , Linda Power[SUP]1[/SUP] , Samantha Westrop[SUP]1[/SUP] , Kelsey McOwat[SUP]1[/SUP] , Helen Campbell[SUP]1[/SUP] , Ruth Simmons[SUP]1[/SUP] , Mary E Ramsay[SUP]1,2[/SUP] , Kevin Brown[SUP]1[/SUP] , Shamez N Ladhani[SUP]1,3[/SUP] , Gayatri Amirthalingam[SUP]1[/SUP]

Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5–98.1 vs 48% (41.0–57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5–98.2 vs 75.0% (57.8–87.9).

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.28.2100634#html_fulltext